R

    Repligen Corporation (RGEN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $180.98
    +4.71 (+2.67%)

    Market Cap: $9.95B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    90%(36/40)
    Avg Surprise
    +18.70%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.46
    Range$0.41 - $0.49
    17 analysts
    EPS Revisions
    7
    0
    7d
    7
    6
    30d
    EPS Estimate Drift
    90d ago$0.47+1.4%
    60d ago$0.47+2.3%
    30d ago$0.47+2.2%
    7d ago$0.46+0.0%
    Current$0.46
    Revenue Consensus
    $207M
    Range$205M - $208M
    18 analysts
    Dec 31, 2026
    EPS Consensus$0.77
    Range$0.73 - $0.79
    20 analysts
    Revenue Consensus
    $227M
    Range$218M - $256M
    21 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.77---
    Sep 26EST
    		-$0.46---
    Jun 26
    		$0.54$0.45+20.00%Beat+45.9%
    Mar 26
    		$0.48$0.39+23.08%Beat+23.1%
    Dec 25
    		$0.49$0.44+11.52%Beat+11.4%
    Sep 25
    		$0.46$0.41+12.20%Beat+4031.6%
    Jun 25
    		$0.37$0.39-5.13%Miss+12.1%
    Mar 25
    		$0.39$0.35+11.43%Beat+39.3%
    Dec 24
    		$0.44$0.42+4.99%Beat+33.3%
    Sep 24
    		$-0.01N/A-103.55%Miss-105.1%
    Jun 24
    		$0.33$0.33+0.00%Beat-37.7%
    Mar 24
    		$0.28$0.30-6.67%Miss-56.3%
    Dec 23
    		$0.33$0.33+0.00%Beat-51.5%
    Sep 23
    		$0.23$0.16+43.75%Beat-70.1%
    Jun 23
    		$0.53$0.48+10.42%Beat-41.8%
    Mar 23
    		$0.64$0.59+8.47%Beat-30.4%
    Dec 22
    		$0.68$0.58+17.24%Beat-16.0%
    Sep 22
    		$0.77$0.68+13.24%Beat-1.3%
    Jun 22
    		$0.91$0.71+28.17%Beat+15.2%
    Mar 22
    		$0.92$0.72+27.78%Beat+35.3%
    Dec 21
    		$0.81$0.65+24.62%Beat+55.8%
    Sep 21
    		$0.78$0.64+21.88%Beat+95.0%
    Jun 21
    		$0.79$0.52+51.92%Beat+88.1%
    Mar 21
    		$0.68$0.42+61.90%Beat+112.5%
    Dec 20
    		$0.52$0.31+67.74%Beat+160.0%
    Sep 20
    		$0.40$0.28+42.86%Beat+53.8%
    Jun 20
    		$0.42$0.28+50.00%Beat+35.5%
    Mar 20
    		$0.32$0.21+52.38%Beat+14.3%
    Dec 19
    		$0.20$0.18+11.11%Beat-4.8%
    Sep 19
    		$0.26$0.19+36.84%Beat+30.0%
    Jun 19
    		$0.31$0.30+3.33%Beat+93.8%
    Mar 19
    		$0.28$0.22+27.27%Beat+64.7%
    Dec 18
    		$0.21$0.21+0.00%Beat+5.0%
    Sep 18
    		$0.20$0.18+11.11%Beat+33.3%
    Jun 18
    		$0.16$0.18-11.11%Miss-20.0%
    Mar 18
    		$0.17$0.15+13.33%Beat+13.3%
    Dec 17
    		$0.20$0.12+66.67%Beat+150.0%
    Sep 17
    		$0.15$0.11+36.36%Beat+87.5%
    Jun 17
    		$0.20$0.15+33.33%Beat-
    Mar 17
    		$0.15$0.13+15.38%Beat-
    Dec 16
    		$0.08$0.07+14.29%Beat-
    Sep 16
    		$0.08$0.08+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio91.87EV/EBITDA59.17x
    Price/FCF91.19xFCF Yield1.10%
    Profitability
    Profit Margin5.29%Operating Margin9.31%
    ROE1.99%ROIC1.43%
    Financial Health
    Debt/Equity0.26xInterest Coverage2.16x
    Current Ratio9.05xQuick Ratio7.64x
    Trading Statistics
    Beta1.01Avg Volume987.23K
    52-Week High$188.7352-Week Low$100.99

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$178.68
    SMA 20$170.78
    SMA 50$152.76
    SMA 200$141.62
    EMA 10$177.27
    EMA 20$170.56
    EMA 50$156.17
    EMA 200$141.29

    MACD

    Line: 9.04Signal: 9.07Hist: -0.03

    ADX

    ADX: 56.5+DI: 29.9-DI: 9.0

    Aroon & PSAR

    Aroon Up72.0
    Aroon DownN/A
    PSAR$188.02

    Bollinger Bands

    Upper Band$189.99
    Lower Band$151.57
    %B Position2250%(Upper)
    Band Width0.77

    RSI (14-Day)

    Neutral
    68.4

    Momentum Oscillators

    Stoch %K67.3
    Stoch %D70.0
    Williams %R-28.9
    ROC (10d)7.1%
    Momentum11.94
    CCI (20d)66.4
    MFI (14d)77.9

    Volatility Measures

    ATR (14d)$6.92(3.8%)
    StdDev (20d)9.61
    Hist Vol35.0%(Moderate)

    Volume Flow

    VWAP$178.69
    OBV13.8M
    AD Line-7.4M
    CMF (20d)0.318

    Volume Metrics

    Avg Vol (20d)986.1K
    Vol Ratio0.8x
    VWMA (20d)$171.03

    Pivot Points

    R3$185.50
    R2$183.42
    R1$179.84
    Pivot Point$177.77
    S1$174.19
    S2$172.12
    S3$168.54

    Advanced Oscillators

    TSI42.18
    Ultimate Osc60.5
    KST220.18

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$204.13M$194.25M$197.91M$188.81M$182.37M$169.17M$167.55M$154.87M$158.84M$153.18M$166.62M$141.19M
    Cost of Revenue$94.09M$85.97M$94.08M$88.29M$89.37M$77.80M$128.71M$77.38M$77.31M$76.39M$88.14M$104.63M
    Gross Profit$110.04M$108.28M$103.83M$100.52M$93.00M$91.37M$38.84M$77.49M$81.53M$76.79M$78.48M$36.56M
    Operating Expenses$96.06M$92.34M$85.96M$83.69M$79.10M$84.79M$75.34M$85.32M$76.06M$73.04M$68.61M$31.87M
    R&D$14.42M$14.46M$13.12M$14.18M$13.97M$12.11M$11.68M$9.71M$10.57M$11.24M$10.29M$10.58M
    SG&A$76.62M$76.54M$74.36M$73.66M$70.91M$70.71M$60.47M$75.61M$65.48M$61.80M$57.63M$55.58M
    Operating Income$13.98M$15.94M$17.87M$16.82M$13.90M$6.58M$-36,501,000$-7,832,000$5.47M$3.75M$9.87M$4.69M
    Interest Income$6.43M$6.34M$6.75M$6.92M$6.58M$7.31M$8.29M$9.13M$9.41M$8.99M$6.02M$6.66M
    Interest Expense$5.66M$5.58M$5.50M$5.41M$5.35M$5.25M$5.46M$5.12M$5.12M$5.03M$13.95M$408,000
    Income Before Tax$14.15M$1.77M$19.11M$17.11M$18.21M$7.94M$-38,608,000$-1,149,000$9.03M$3.69M$1.86M$11.38M
    Income Tax Expense$9.14M$-6,561,000$5.83M$2.20M$3.35M$2.11M$-4,739,000$-495,000$3.31M$399,000$18.32M$-5,542,000
    Net Income$5.01M$8.33M$13.29M$14.91M$14.87M$5.83M$-33,869,000$-654,000$5.71M$3.30M$-16,450,000$16.92M
    EBITDA$41.62M$29.92M$27.45M$54.45M$45.87M$33.11M$-19,112,000$7.45M$29.95M$24.84M$28.13M$25.64M
    EBIT$13.38M$1.01M$17.85M$15.61M$16.98M$5.88M$-41,439,000$-5,157,000$4.73M$-269,000$9.79M$5.13M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RGEN

    Government Contracts

    Gov Obligations (TTM)
    $174560
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    1
    Avg Remaining Term
    107.6 mo

    Top agency: Department of Health and Human Services at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    75F40126P00067Department of Health and Human ServicesFood and Drug Administration$174560May 28, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Repligen (NASDAQ: RGEN) CEO trades shares at $180 under 10b5-1 plan

    Repligen (NASDAQ: RGEN) CEO Olivier Loeillot exercised stock options for 5,426 shares at $141.79 per share and simultaneously sold these shares at $180.00 per share on August 20, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted on August 19, 2025. After the sale, Loeillot holds 10,852 stock options, with additional shares set to vest on September 3, 2026, and September 3, 2027.

    Stock Titan•8/21/26•
    Neutral

    Repligen Jumps 5.4% Amid Sector-Wide Rally

    Repligen Corporation (RGEN) saw its stock surge by 5.4% on Thursday, closing at $185.84, as part of a broad sector-wide rally in bioprocessing and life sciences stocks. This gain was not company-specific but rather indicative of shifting investor sentiment and correlated movement across its peers like Thermo Fisher Scientific, Bio-Rad Laboratories, Revvity, and Bruker Corporation. The rally suggests a sector-wide catalyst, with investors re-evaluating shared fundamentals within the medical instruments and supplies industry.

    AlphaStreet•8/20/26•
    Neutral

    Repligen (NASDAQ: RGEN) plan covers 5,426-share sale after option exercise

    Repligen Corp (RGEN) has announced through a Rule 144 notice that Olivier Loeillot intends to sell up to 5,426 shares of common stock. This sale, facilitated by Fidelity Brokerage Services LLC, is scheduled for on or after August 20, 2026, on NASDAQ, and is associated with a stock option exercise. The filing details the number of shares, the intended sale date, and relevant SEC file information, with no stated positive or negative impacts on the company from the filing.

    Stock Titan•8/20/26•
    Neutral

    Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com

    Repligen Corporation's stock has reached a new 52-week high of $176.52, reflecting a significant 36.68% increase over the past year and a market capitalization of $9.38 billion. While the company demonstrates strong returns and recent revenue growth of 16.49%, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. The firm recently surpassed Q2 2026 earnings expectations, but analysts like Canaccord Genuity maintain a "Hold" rating.

    Investing.com Nigeria•8/20/26•
    Bullish

    Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com

    Repligen Corporation (RGEN) stock has hit a new 52-week high of $176.52, reflecting a significant 1-year change of 36.68% and a market capitalization of $9.38 billion. This surge follows strong Q2 2026 earnings, where the company surpassed Wall Street expectations for both adjusted earnings per share and revenue, prompting an increased full-year outlook. Despite this, Canaccord Genuity has reiterated a "Hold" rating with a price target of $145.

    Investing.com South Africa•8/20/26•
    Bullish

    Frequently Asked Questions About RGEN

    Does RGEN pay dividends?
    Repligen Corporation (RGEN) does not currently pay a regular dividend.
    What is RGEN's P/E ratio?
    Repligen Corporation has a price-to-earnings (P/E) ratio of 91.87.
    What is RGEN's market cap?
    Repligen Corporation (RGEN) has a market capitalization of $9.95B with a current stock price of $180.98.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In